Updated Aug 7 at 7:03pm ET.
Follow Legend Biotech to never miss an important update.
Ying Huang has stepped down as CEO and board member effective immediately. He will stay on as an advisor through August to help with the handoff. Alan Bash, who leads the company's business operations, has been named interim CEO.
A sudden leadership change at a biotech company in the middle of a major product rollout can be disruptive. The company is currently focused on scaling up manufacturing for Carvykti, its treatment for multiple myeloma, a type of blood cancer. While the drug's clinical success is well-established, the new leadership must prove it can manage the complex logistics of producing cell therapies at a much larger scale.
Source: GlobeNewsWire
UBS analysts downgraded the stock from a buy-equivalent rating to Neutral and set a price target of $28. This is a sharp drop from the average analyst target of $53.
While the company's main drug, Carvykti, continues to show strong results in treating cancer, a downgrade like this often suggests concerns about how quickly the company can grow or how much it will cost to build out its labs. For a company that is not yet profitable, these manufacturing and spending hurdles are just as important as the science itself.
Source: UBS
Analysts have recently lowered their price targets following the company's announcement of a CEO transition. Most analysts, 15 of 19, still rate the stock a buy with an average target price suggesting 154% upside from today.
The company has a habit of beating analyst expectations, often by a wide margin. This suggests management is conservative with its forecasts while the business outruns expectations.
| Expectation | |
|---|---|
| EPS | $0.06 |
| Revenue | $356M |
Follow Legend Biotech to get the latest and most important updates.
Follow LEGN
